Leslie Edwards
Energy Biosciences Institute(US)Caribou Biosciences (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, CRISPR and Genetic Engineering, T-cell and B-cell Immunology, Biosimilars and Bioanalytical Methods, Advanced biosensing and bioanalysis techniques
Most-Cited Works
- → Mapping the genomic landscape of CRISPR–Cas9 cleavage(2017)458 cited
- → Harnessing type I CRISPR–Cas systems for genome engineering in human cells(2019)121 cited
- → High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models(2024)29 cited
- → Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness(2023)22 cited
- → CLL-1-Targeted Allogeneic CAR-T Cells Exhibit High on-Target Specificity and Potent Cytotoxicity in Preclinical Models of Acute Myeloid Leukemia(2023)5 cited
- → Abstract 3201: CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune cell-mediated rejection, for patients with relapsed or refractory acute myeloid leukemia(2023)3 cited
- → Abstract 6323: Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent toxicity in acute myeloid leukemia (AML) xenograft models(2024)2 cited
- → Abstract LB009: A BCMA-specific allogeneic CAR-T cell therapy (CB-011) genome-engineered to express an HLA-E fusion transgene to prevent immune cell rejection(2022)1 cited
- → Author Correction: Mapping the genomic landscape of CRISPR–Cas9 cleavage(2023)1 cited
- → Figure S7. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models(2024)